Pfizer Inc. Press Releases https://investors.pfizer.com/generated by Q4Fri, 15 May 2026 11:46:37 -0400Copyright Q4 Inc. All rights reserved.European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors16b4ada8-3686-4117-ad58-bbd7c1544aadhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/European-Commission-Approves-Pfizers-HYMPAVZI-for-the-Treatment-of-Adults-and-Adolescents-with-Hemophilia-A-or-B-With-Inhibitors/default.aspxWed, 13 May 2026 06:45:00 -0400Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance958e00eb-85a5-4305-81ea-1db207c3a614https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Reports-Strong-First-Quarter-Results-And-Reaffirms-2026-Guidance/default.aspxTue, 05 May 2026 06:45:00 -0400Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myelomaba598b7e-9765-4ecd-a8b7-efb654c3a986https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizers-ELREXFIO-Significantly-Improves-Progression-Free-Survival-for-Double-Class-Exposed-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxWed, 29 Apr 2026 06:45:00 -0400Pfizer Reaches Three Settlement Agreements for VYNDAMAXa5db4be9-8439-4452-8481-e7c32eca4c1dhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Reaches-Three-Settlement-Agreements-for-VYNDAMAX/default.aspxTue, 28 Apr 2026 10:17:00 -0400Pfizer Declares Second-Quarter 2026 Dividendd68d7a88-e6b6-43a4-899a-06d1a2bb9c86https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Declares-Second-Quarter-2026-Dividend/default.aspxWed, 22 Apr 2026 16:45:00 -0400Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 20266849236f-74e4-4c17-82d7-31b4c19b9052https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Showcases-Oncology-Innovation-and-Next-Generation-Pipeline-at-ASCO-2026/default.aspxTue, 21 Apr 2026 11:51:00 -0400U.S. FDA Grants Priority Review to sBLA for PADCEV + Keytruda as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility3cead915-bdd3-4e5f-b1cf-a1256f96a8echttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/U-S--FDA-Grants-Priority-Review-to-sBLA-for-PADCEV--Keytruda-as-Perioperative-Treatment-for-Muscle-Invasive-Bladder-Cancer-Regardless-of-Cisplatin-Eligibility-2026--aYF8zy9gB/default.aspxMon, 20 Apr 2026 06:45:00 -0400Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders394ebd36-0990-4cc9-8c16-9180ca1079f4https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Shareholders-to-View-and-Listen-to-Webcast-of-April-23-Virtual-2026-Annual-Meeting-of-Shareholders/default.aspxThu, 09 Apr 2026 10:00:00 -0400Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts3c81e691-874d-40e2-9cb9-0916d51ceaffhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-View-and-Listen-to-Webcast-of-May-5-Conference-Call-with-Analysts/default.aspxTue, 24 Mar 2026 10:00:00 -0400Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Triald706e687-95b3-4ca8-9233-a35cb6fff2dfhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-and-Valneva-Announce-Lyme-Disease-Vaccine-Candidate-Demonstrates-Strong-Efficacy-in-Phase-3-VALOR-Trial/default.aspxMon, 23 Mar 2026 06:45:00 -0400